We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Purine Biosynthetic Enzyme PAICS as a Central Mediator of DNA Damage and Cerebellar Atrophy in C9orf72-ALS

MedXY Editorial Team•Mar 11, 2026•Clinical Updates
ALSC9orf72CerebellumDNA損傷PAICS

Highlights

  • C9orf72 loss-of-function in vivo triggers cerebellar atrophy and depletion of Purkinje and Granule cells, preceding the onset of overt motor defects.
  • Single-cell transcriptomics identifies the downregulation of paics, a gene essential for purine biosynthesis, as a primary driver of neuronal loss in the cerebellum.
  • PAICS deficiency is validated in human post-mortem cerebellar tissue and C9orf72 iPSC-derived motor neurons, suggesting a conserved mechanism across species.
  • Knockout of paics leads to catastrophic DNA damage and repair (DDR) defects; conversely, restoring PAICS expression rescues the neurodegenerative phenotype and motor function.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Survival Estimates and Predictors in Genetic Frontotemporal Dementia: Insights from an International Retrospective Cohort StudyThis review synthesizes international evidence on survival in genetic frontotemporal dementia (FTD), highlighting key predictors such as age at onset, clinical phenotype, and motor symptoms, and discusses implications for patient care and tAug 5, 2026Statistical Inconsistency in ALS Trials: How Analysis Methods Skew Treatment EfficacyA study reveals significant variability in ALSFRS-R analysis methods across 45 ALS trials, impacting treatment effect estimates and increasing false-positive risks, with implications for clinical decision-making and drug development.Apr 24, 2026PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM TrialThe Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective stMar 30, 2026PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.
Mar 18, 2026
Somatic Mosaicism in the Motor Cortex: A New Frontier in Understanding Sporadic ALS PathogenesisThis study identifies somatic gene mutations in excitatory neurons of the motor cortex as a potential driver of sporadic ALS, challenging the traditional view of the disease’s genetic origins.Mar 12, 2026
“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALSA Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to tradDec 31, 2025